The aim of this study was to investigate the association of two genetic polymorphisms, MDM2 SNP309 and TP53 R72P, with incidence of neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide (FEC). Primary breast cancer patients (n = 216) treated with adjuvant FEC (60, 75 or 100 mg/m2) were included in this study. The association of genotypes of MDM2 SNP309 and TP53 R72P, determined by TaqMan SNP Genotyping Assays, with febrile neutropenia (FN) was investigated. In the patients treated with FEC100, G/G genotype for MDM2 SNP309 (G/G genotypeMDM2) was significantly (P < 0.01) associated with a lower incidence (5.3 vs. 39.2%) of severe neutropenia (<100/mm3) than with T/T + T/G genotypesMDM2, and C/C genotype for TP53 R72P (C/C genotypeTP53) was significantly (P = 0.03) associated with a higher incidence (58.3 vs. 27.3%) of FN than with G/G + G/C genotypesTP53. The combination of C/C genotypeTP53 and T/T + T/G genotypeMDM2 showed the highest risk for developing severe neutropenia (83.3%) and FN (62.5%) than any other combinations. In the patients treated with FEC60 or FEC75, there was no significant association of MDM2 SNP309 and TP53 R72P with severe neutropenia and FN. MDM2 SNP309 and TP53 R72P are significantly associated with severe neutropenia and FN, respectively, in breast cancer patients treated with FEC100, and especially their combination may be a useful predictor of severe neutropenia and FN.
Breast cancer FEC100 MDM2 SNP309 Neutropenia TP53 R72P
This is a preview of subscription content, log in to check access.
This study was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan.
Conflict of interest
S. Noguchi has received research grants and honoraria from Pfizer.
Roche H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664–5671PubMedCrossRefGoogle Scholar
Mouret-Reynier MA, Abrial CJ, Ferrière JP et al (2004) Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin. Clin Breast Cancer 5:303–307PubMedCrossRefGoogle Scholar
French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5 year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602–611Google Scholar
Abe H, Umeda T, Tanaka M et al (2010) Feasibility of FEC 100 followed by DOC 100 as adjuvant chemotherapy for breast cancer. Gan To Kagaku Ryoho 37:1483–1487PubMedGoogle Scholar
Toi M, Nakamura S, Kuroi K et al (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531–539PubMedCrossRefGoogle Scholar
Nayak MS, Yang JM, Hait WN (2007) Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 67:5831–5839PubMedCrossRefGoogle Scholar
Tommiska J, Eerola H, Heinonen M et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098–5103PubMedCrossRefGoogle Scholar
Xu Y, Yao L, Ouyang T et al (2005) p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328–7333PubMedCrossRefGoogle Scholar
Xu Y, Yao L, Zhao A et al (2008) Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer 122:2761–2766PubMedCrossRefGoogle Scholar
Toyama T, Zhang Z, Nishio M et al (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9:R34PubMedCrossRefGoogle Scholar
Dumont P, Leu JI, Della Pietra AC 3rd, George D, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365PubMedCrossRefGoogle Scholar
Sullivan A, Syed N, Gasco M et al (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23:3328–3337PubMedCrossRefGoogle Scholar
Schmidt MK, Tommiska J, Broeks et al (2009) Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res 11:R89PubMedCrossRefGoogle Scholar
Boersma BJ, Howe TM, Goodman JE et al (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98:911–919PubMedCrossRefGoogle Scholar
Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205PubMedCrossRefGoogle Scholar
Tsuda H, Sasano H, Akiyama F et al (2002) Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by herceptest, nichirei polyclonal antibody, CB11 and TAB 250 in breast carcinoma. Pathol Int 52:126–134PubMedCrossRefGoogle Scholar
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRefGoogle Scholar
Khrunin AV, Moisseev A, Gorbunova V, Limborska S (2010) Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 10:54–61PubMedCrossRefGoogle Scholar
O’Connor PM, Jackman J, Bae I et al (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285–4300PubMedGoogle Scholar
Kandioler-Eckersberger D, Ludwig C, Rudas M et al (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50–56PubMedGoogle Scholar
Chrisanthar R, Knappskog S, Løkkevik E et al (2008) CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 26:e3062CrossRefGoogle Scholar
Geisler S, Lønning PE, Aas T et al (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 6:2505–2512Google Scholar
Bunz F, Hwang PM, Torrance C et al (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269PubMedCrossRefGoogle Scholar
Bertheau P, Turpin E, Rickman DS et al (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4:e90PubMedCrossRefGoogle Scholar